Denali Therapeutics (NASDAQ:DNLI) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Denali Therapeutics (NASDAQ:DNLI - Free Report) had its target price raised by Jefferies Financial Group from $40.00 to $45.00 in a report released on Friday, Benzinga reports. They currently have a buy rating on the stock.

Other research analysts also recently issued reports about the company. Cantor Fitzgerald downgraded Denali Therapeutics from an "overweight" rating to a "neutral" rating in a research report on Monday, October 7th. Bank of America upped their price objective on Denali Therapeutics from $25.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. Raymond James reiterated a "market perform" rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Citigroup upped their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a "buy" rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research note on Friday, October 11th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $38.90.

Denali Therapeutics Trading Up 4.2 %

Shares of DNLI stock traded up $1.09 during mid-day trading on Friday, reaching $27.05. The stock had a trading volume of 837,709 shares, compared to its average volume of 1,078,313. The company has a market cap of $3.87 billion, a P/E ratio of -9.46 and a beta of 1.38. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $32.13. The business has a 50-day simple moving average of $27.33 and a 200 day simple moving average of $23.01.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.09. The business had revenue of $1.00 million for the quarter, compared to analysts' expectations of $10.00 million. The business's revenue was down 99.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.30 earnings per share. Research analysts anticipate that Denali Therapeutics will post -2.53 EPS for the current year.

Insider Activity at Denali Therapeutics

In related news, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now directly owns 235,807 shares of the company's stock, valued at approximately $6,529,495.83. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company's stock, valued at approximately $6,529,495.83. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steve E. Krognes sold 30,000 shares of Denali Therapeutics stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now directly owns 29,096 shares in the company, valued at approximately $844,656.88. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its position in Denali Therapeutics by 879.5% in the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company's stock valued at $48,000 after acquiring an additional 1,847 shares in the last quarter. CWM LLC increased its stake in Denali Therapeutics by 43.6% during the 3rd quarter. CWM LLC now owns 2,153 shares of the company's stock worth $63,000 after buying an additional 654 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Denali Therapeutics by 48.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company's stock worth $53,000 after buying an additional 807 shares in the last quarter. Assetmark Inc. boosted its position in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company's stock valued at $111,000 after buying an additional 580 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics during the first quarter valued at about $88,000. 92.92% of the stock is currently owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.